Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$24.05 +0.7%	$21.93	$12.21 ▼ $41.31	$697.78M	-0.27	643,024 shs	212,764 shs
BDSI BioDelivery Sciences International	$5.59	$5.58	$2.50 ▼ $5.62	$577.05M	0.56	3.34 million shs	2.09 million shs
CRBP Corbus Pharmaceuticals	$7.61 -1.8%	$7.75	$4.64 ▼ $61.90	$94.35M	3.05	343,453 shs	77,721 shs
KURA Kura Oncology	$5.91 +1.7%	$6.12	$5.41 ▼ $23.48	$507.33M	0.4	1.26 million shs	781,540 shs
URGN Urogen Pharma	$13.49 +4.1%	$9.67	$3.42 ▼ $18.15	$626.13M	1.02	1.08 million shs	737,414 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+7.01%	+13.74%	+29.90%	-3.43%
BDSI BioDelivery Sciences International	0.00%	0.00%	0.00%	0.00%	0.00%
CRBP Corbus Pharmaceuticals	0.00%	+2.81%	-13.55%	+51.55%	-84.68%
KURA Kura Oncology	0.00%	+4.23%	-10.05%	+0.34%	-70.54%
URGN Urogen Pharma	0.00%	0.00%	+162.45%	+31.61%	-10.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	2.3046 of 5 stars	3.4	1.0	0.0	0.0	2.2	2.5	0.6
BDSI BioDelivery Sciences International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	3.7817 of 5 stars	3.6	0.0	0.0	4.7	0.9	2.5	0.6
KURA Kura Oncology	4.556 of 5 stars	4.4	3.0	0.0	4.7	1.9	0.8	0.6
URGN Urogen Pharma	4.4608 of 5 stars	4.5	2.0	0.0	4.5	1.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	76.23% Upside
BDSI BioDelivery Sciences International	0.00	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	568.70% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	314.55% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	143.57% Upside

Current Analyst Ratings Breakdown

Latest KURA, BDSI, URGN, CRBP, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$111.87M	6.31	N/A	N/A	$2.33 per share	10.32
BDSI BioDelivery Sciences International	$166.70M	3.46	$0.36 per share	15.42	$1.90 per share	2.94
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$11.69 per share	N/A
KURA Kura Oncology	$67.99M	7.53	N/A	N/A	$5.32 per share	1.11
URGN Urogen Pharma	$91.87M	6.77	N/A	N/A	($0.21) per share	-64.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
BDSI BioDelivery Sciences International	$84.86M	$0.83	6.74	8.47	N/A	50.90%	21.25%	10.56%	N/A
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.22	N/A	N/A	N/A	N/A	-36.87%	-32.87%	8/5/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest KURA, BDSI, URGN, CRBP, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
BDSI BioDelivery Sciences International	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
BDSI BioDelivery Sciences International	0.29	2.45	2.17
CRBP Corbus Pharmaceuticals	N/A	11.82	11.82
KURA Kura Oncology	0.02	8.07	8.07
URGN Urogen Pharma	N/A	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
BDSI BioDelivery Sciences International	64.40%
CRBP Corbus Pharmaceuticals	64.64%
KURA Kura Oncology	N/A
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
BDSI BioDelivery Sciences International	9.98%
CRBP Corbus Pharmaceuticals	3.60%
KURA Kura Oncology	6.40%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
BDSI BioDelivery Sciences International	200	103.23 million	92.93 million	Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.80 million	Optionable
KURA Kura Oncology	130	86.58 million	81.03 million	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

KURA, BDSI, URGN, CRBP, and ANAB Headlines

Recent News About These Companies

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer

July 6 at 6:29 AM | msn.com

Harel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)

July 4 at 8:14 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 2, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

July 1, 2025 | globenewswire.com

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

June 30, 2025 | globenewswire.com

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 30, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27, 2025 | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 23, 2025 | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (â€œUroGenâ€ or the â€œCompanyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

June 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 22, 2025 | prnewswire.com

Stocks With Rising Relative Price Strength: UroGen Pharma

June 20, 2025 | msn.com

Urogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What Happened

June 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 18, 2025 | globenewswire.com

HC Wainwright Decreases Earnings Estimates for Urogen Pharma

June 18, 2025 | marketbeat.com

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

June 17, 2025 | msn.com

UroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?

June 17, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 17, 2025 | prnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May

June 17, 2025 | marketbeat.com

URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses

June 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, BDSI, URGN, CRBP, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$24.04 +0.17 (+0.69%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$23.57 -0.47 (-1.97%)

As of 07/3/2025 04:36 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

BioDelivery Sciences International NASDAQ:BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Corbus Pharmaceuticals NASDAQ:CRBP

$7.61 -0.14 (-1.83%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$7.60 0.00 (-0.04%)

As of 07/3/2025 04:08 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Kura Oncology NASDAQ:KURA

$5.91 +0.10 (+1.72%)

Closing price 07/3/2025 03:35 PM Eastern

Extended Trading

$5.91 0.00 (0.00%)

As of 07/3/2025 04:58 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Urogen Pharma NASDAQ:URGN

$13.49 +0.53 (+4.09%)

Closing price 07/3/2025 03:11 PM Eastern

Extended Trading

$13.39 -0.10 (-0.74%)

As of 07/3/2025 04:59 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time